Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study

Office of New Drugs Director John Jenkins reassured panel members of the agency’s ability to assess civil penalties or cite a drug for misbranding if sponsors fail to meet post-market study obligations.